Study Treatment AdministrationDetails regardin g preparation and administration are provided in site training materials. In all study part s, participants will be observed for at least 60 minutes following the completion of B MS-986226 infusion due to the potential ris k of, and to monitor for, infusion reactio ns. Revised Protocol No.: 04 Date: 31-May-2019 28 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 2-2: On-treatment Procedural Outline (CA021002) Procedures for Safety Cohort, and Parts A, B, C, D and Ea,bC1C2 to beyondC2 OnlyC2 OnlyNotes Procedure D1 D2D8 ±±1 daysD15 ±1 daysD22 ±1 daysD1 D2D8 ±1 daysEOT c,d,e All Parts: PremedicationXXIn all study part s, participants are recommended t o receive premedication 30 minutes prio r to infusion of any study drug, to reduce the risk of infusion-related reactions, as de scribed in Section 7.1 and Section 7.3.6 .Any modification to the recommended r egimen must be discussed and agreed upon with BMS Medical Monitor/Study Director. All Parts: BMS-986226 AdministrationXXUse vials assigned per IRT. Safety Cohort and Part A BMS-986226 will be administered every 4 weeks on the first day of each cycle Parts B1 and C1: BMS-986226 will be administered on Day 1 every 12 weeks (Cycle 1 Day1, Cycle 4 Day1, Cycle 7 Day 1, etc) Parts B2 and C2: BMS-986226 will be administered every 4 weeks on the fir st day of each cycle Parts D and E: The dose and sc hedule of BMS-986226 will be determined b ased on available data from Parts A, B1, B2, C1 and C2. Revised Protocol No.: 04 Date: 31-May-2019 29 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 2-2: On-treatment Procedural Outline (CA021002) Procedures for Safety Cohort, and Parts A, B, C, D and Ea,bC1C2 to beyondC2 OnlyC2 OnlyNotes Procedure D1 D2D8 ±±1 daysD15 ±1 daysD22 ±1 daysD1 D2D8 ±1 daysEOT c,d,e Parts B1, B2, and D ONLY : Nivolumab AdministrationXXUse vials assigned per IRT. Nivolumab is administered O NLY for those participants enrolled in Part s B1, B2, and D. Parts C1, C2, and E ONLY : Ipilimumab AdministrationXXUse vials assign ed per IRT. Ipilimumab is administered O NLY for those participants enrolled in Part s C1, C2 and E. aThe procedural outline for participants who receive additional cycles are outlined in Table 2-4 . bParticipants taking 2 or 8 mg of BMS-986226 in the Pr eliminary Safety Cohorts will follow the same procedure schedule as in Par t A. In the event that participants taking 2 or 8 mg of BMS-986226 should be permitted to intra-dos e escalate up to 8 and/or 25 mg, the sampling schedule should be restarted at Cycle 1 Day 1 at each dose escalation, and an additional tumor biopsy may be optionally re-collected at C1D15. cEOT is defined as the visit where a decision is made to discontinue the participant from treatment. dFor participants who complete all scheduled cycles of therapy, the EOT visit will be the same as the last scheduled and complet ed on-treatment visit (eg, Cycle 6 Day 175) and the start of the Week 1 safety follow-up visit. eFor participants who do not complete all scheduled cycles of therapy, the EOT visit will be the most recent on-treatment vi sit (with all available safety and response data) and does not need to be repeated, and it will be considered the start of the Week 1 safety follow-up visit. Abbreviations: AE = adverse event; C1 = Cy cle 1; C2 = Cycle 2; C3 = Cycle 3; C5 = Cycle 5; C6 = Cycle 6; CB C = complete blood c ount; ; ECOG = Eastern Cooperative Oncol ogy Group; EOT = end of treatment; D1 = Day 1; D2 = D ay 2; D4 = Day 4; D8 = Day 8; D15 = Day 15; D21 = Day 21; hCG = human chorion ic gonadotropin; IRT = Interactive Response Technology; PE = physical examination; PK = pharmacokinetic; PD = pharmacodynamic; Q12W = every 12 weeks; RECIST v1.1 = Response Evaluation Criteria in Solid Tumors Version 1.1; T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid-stimulating hormone; WOCBP = women of childbearing potential. Revised Protocol No.: 04 Date: 31-May-2019 30 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 2-3: Follow-up Procedural Outline (CA021002) ProcedureSafety Follow-upaSurvival/Response Long-term Follow-up NotesFU 1 30 days (±±7 days) FU 2 60 days (±7 days)FU 3 100 days (±7 days)Begins After Completion of Safety Follow-up Q12W (Q12W ±2 weeks) Until 2 Years After Last Dose of Study Treatment Safety Assessments Symptom-directed PE X X X Symptom-directed only. ECOG Performance Status X X X ECOG score (Appendix 7) Vital Signs X X X See no te in Table 2-1 .